Cargando…
Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
Background. Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases of 2 patients who had surgery after sorafenib. Results. The...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226249/ https://www.ncbi.nlm.nih.gov/pubmed/22135750 http://dx.doi.org/10.4061/2011/791013 |
_version_ | 1782217586006556672 |
---|---|
author | Barbier, L. Muscari, F. Le Guellec, S. Pariente, A. Otal, P. Suc, B. |
author_facet | Barbier, L. Muscari, F. Le Guellec, S. Pariente, A. Otal, P. Suc, B. |
author_sort | Barbier, L. |
collection | PubMed |
description | Background. Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases of 2 patients who had surgery after sorafenib. Results. The patients had a large hepatocellular carcinoma in the right liver with venous neoplastic thrombi (1 in the right portal branch, 1 in the right hepatic vein). After 9 months of sorafenib, reassessment showed that tumours had decreased in size with a necrotic component. A right hepatectomy with thrombectomy was performed, and histopathology showed 35% to 60% necrosis. One patient had a recurrence after 6 months and had another liver resection; they are both recurrence-free since then. Conclusion. Sorafenib can downstage hepatocellular carcinoma and thus could represent a bridge to surgery. It may be possible to select patients in good general condition with partial regression of the tumour with sorafenib for a treatment in a curative intent. |
format | Online Article Text |
id | pubmed-3226249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-32262492011-12-01 Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib Barbier, L. Muscari, F. Le Guellec, S. Pariente, A. Otal, P. Suc, B. Int J Hepatol Case Report Background. Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases of 2 patients who had surgery after sorafenib. Results. The patients had a large hepatocellular carcinoma in the right liver with venous neoplastic thrombi (1 in the right portal branch, 1 in the right hepatic vein). After 9 months of sorafenib, reassessment showed that tumours had decreased in size with a necrotic component. A right hepatectomy with thrombectomy was performed, and histopathology showed 35% to 60% necrosis. One patient had a recurrence after 6 months and had another liver resection; they are both recurrence-free since then. Conclusion. Sorafenib can downstage hepatocellular carcinoma and thus could represent a bridge to surgery. It may be possible to select patients in good general condition with partial regression of the tumour with sorafenib for a treatment in a curative intent. SAGE-Hindawi Access to Research 2011 2011-03-20 /pmc/articles/PMC3226249/ /pubmed/22135750 http://dx.doi.org/10.4061/2011/791013 Text en Copyright © 2011 L. Barbier et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Barbier, L. Muscari, F. Le Guellec, S. Pariente, A. Otal, P. Suc, B. Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib |
title | Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib |
title_full | Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib |
title_fullStr | Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib |
title_full_unstemmed | Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib |
title_short | Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib |
title_sort | liver resection after downstaging hepatocellular carcinoma with sorafenib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226249/ https://www.ncbi.nlm.nih.gov/pubmed/22135750 http://dx.doi.org/10.4061/2011/791013 |
work_keys_str_mv | AT barbierl liverresectionafterdownstaginghepatocellularcarcinomawithsorafenib AT muscarif liverresectionafterdownstaginghepatocellularcarcinomawithsorafenib AT leguellecs liverresectionafterdownstaginghepatocellularcarcinomawithsorafenib AT parientea liverresectionafterdownstaginghepatocellularcarcinomawithsorafenib AT otalp liverresectionafterdownstaginghepatocellularcarcinomawithsorafenib AT sucb liverresectionafterdownstaginghepatocellularcarcinomawithsorafenib |